Navigation Links
Study Compares Risk With Two Diabetes Drugs
Date:8/24/2010

217 patients taking rosiglitazone and 217 taking pioglitazone.

The study included 36,628 patients who had submitted insurance claims to WellPoint affiliates for either of the two diabetes medications between 2001 and 2005. Patients' average age was 54, and 58 percent were male. Wertz and her team obtained death records from the National Death Index, a central database administered by the National Center for Health Statistics.

The investigators divided patients into two equal groups, one receiving rosiglitazone and the other, pioglitazone. After adjusting the data for (removing/minimizing the effect of) age, gender, prior heart and blood vessel diseases and diabetes-related complications and severity indicators, they compared the incidence of heart attack, heart failure and death for an average 14 months of treatment and 19 months of post-treatment follow-up.

Diabetes is a disease in which the body cannot adequately produce the hormone insulin or uses it improperly. The disease can cause a potentially dangerous buildup of sugar in the blood and also increases the risk of heart and blood vessel diseases, which are the main causes of death for people with diabetes.

Rosiglitazone, sold under the trade name Avandia by GlaxoSmithKline, and pioglitazone, sold as Actos by Takeda Pharmaceuticals, belong to the same class of drugs, called TZDs or thiazolidinediones. They help the body use insulin more effectively by boosting the body's sensitivity to the hormone and thus help control blood sugar.

This study has results different from earlier ones that found a greater risk of heart attack among rosiglitazone users compared to patients on other treatments or placebo. In 2007, the Food and Drug Administration decided that the benefits of rosiglitazone outweighed the risks, and it remained on the market although its use decreased significantly. In July 2010, an FDA advisory committee again reviewed numerous studies, including this s
'/>"/>

SOURCE American Heart Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Levi & ... Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning possible violations ... issued by the Company in connection with its study ... TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. ... or by telephone at (212) 363-7500, toll-free: (877) ...
(Date:3/27/2015)... 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, ... approved the grant of an aggregate of 236,070 options ... consultants of the Company pursuant to the Company,s Stock ... expire on the tenth anniversary of the date of ... anniversary of the date of grant and 50,000 are ...
(Date:3/27/2015)... MONTREAL , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 ... of a working group on the biopharmaceutical industry. However, ... medicines budget. "We commend the government,s intent ... the announcement of measures to promote Quebec,s ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... , NEW YORK, Oct. 2 Business ... today released "The Role of ISO 9000 in Document ... certification for its Document Review Services, Quality Management System. ... developing a document review Quality Management System (QMS), where ...
... Oct. 1 Algos Therapeutics Inc., a Minnesota-based global ... of Dr. Ganesh Iyer as its new president and ... , "We were incredibly fortunate to have attracted such ... Algos," stated Gary Smaby, Algos Board Chair and managing ...
Cached Medicine Technology:BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes 'Quality Equals Defensibility' 2BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes 'Quality Equals Defensibility' 3Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO 2
(Date:3/27/2015)... 27, 2015 Ticket Down is a reputable ... Center in Omaha, Nebraska on Friday, May 8th and ... concert dates will be added in Omaha as Garth has ... , The Garth Brooks World Tour is continuing its run ... that Garth Brooks and Trisha Yearwood will bring their act ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
(Date:3/27/2015)... MN (PRWEB) March 27, 2015 ... Minnesotans for Healthy Kids Coalition Lobby Day to ... Statewide Health Improvement Program (SHIP). Everlast Climbing ... 2015 PE Bill SF343/HF498 which would strengthen physical ... annual student assessments and other measures to strengthen ...
(Date:3/27/2015)... 2015 Smile Brands Inc. ( http://www.smilebrands.com ... support services to dental groups in the United States, ... Castle Dental office in Hendersonville, TN. , ... this new Castle Dental office provides families with a ... in comprehensive, quality dental care. Hendersonville marks the eleventh ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3
... Common Office Environments StudiedBOULDER, Colo., May 11 ... company that provides comprehensive and cost-effective ergonomic interventions ... improve productivity, today announced that John Wiley and ... journals has published a book titled "Safety Manager,s ...
... an invited panelist in the second annual SOA in Healthcare conference to ... ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, Dave Shaver, will ... to be held on June 2 - 4 in Chicago, Illinois. ...
... - Easy-to-swallow formulation provides important new alternative for patientsRESEARCH ... GSK ) announced today that the U.S. Food ... Orally Disintegrating Tablets. Lamictal ODT uses a ... a tablet that has a pleasant taste and disintegrates ...
... 11 Lambert, Edwards & Associates (LE&A) ... growing roster of health care clients.Aspirus is a community-directed ... care services to residents in north-central Wisconsin and the ... is consistently recognized as one of the nation,s premier ...
... Services and ProCitius Research jointly announce a strategic alliance created to ... ... Toronto, Canada and Chennai, India (PRWEB) - Dalton Pharma ... provide clients with contract chemistry services of exceptional value. ...
... HHS Report Released During National Women,s Health Week Points ... new report released today on gender-based differences in mental ... men to suffer from major depression. The report ... the effect trauma and violence can have on long ...
Cached Medicine News:Health News:Office Ergonomics Book Reveals Early-Stage Solutions 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 2Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 4Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 5Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 6Health News:Lambert, Edwards & Associates Named Agency of Record for Aspirus, Inc. 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 3Health News:Women at Greater Risk for Depression and Anxiety 2Health News:Women at Greater Risk for Depression and Anxiety 3
Ideal for breast compression and contouring breast cups....
Ideal for breast compression with adjustable hook and eye closure....
Female Mini-VEST, Front Closure, X-Firm...
Male Support Brief...
Medicine Products: